Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Second Cancers in Adults with Acute Promyelocytic Leukemia (APL) Treated with or without Arsenic Trioxide (ATO): A SEER-Medicare Analysis

Kelly J. Norsworthy, MD, Steven T. Bird, PhD PharmD, MS, Armen Avagyan, MS, Yuchen Li, MS, Sandia Akhtar, BS, Jiemin Liao, MA, Michael Wernecke, BA, Albert B. Deisseroth, MD PhD, Meredith Chuk, MD, Thomas E. MaCurdy, PhD, Richard Swain, PhD, Jeffrey A. Kelman, MD MMSc, Ann T. Farrell, MD, Richard Pazdur, MD, Gideon Blumenthal, MD, David J. Graham, MD MPH

Blood (2019) 134 (Supplement_1): 3497.

https://doi.org/10.1182/blood-2019-130295

Published: 2019

Journal Articles

Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA)

Kelly J. Norsworthy, MD, Flora Mulkey, MS, Ashley F. Ward, MD, Donna Przepiorka, MDPhD, Albert B. Deisseroth, MD PhD, Ann T. Farrell, MD, Richard Pazdur, MD

Blood (2018) 132 (Supplement 1): 288.

https://doi.org/10.1182/blood-2018-99-117426

Published: 2018

Journal Articles

Response Rate, Event-Free Survival (EFS), and Overall Survival (OS) in Newly-Diagnosed Acute Myeloid Leukemia (AML): U.S. Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses

Kelly J. Norsworthy, MD, Xin Gao, PhD, Chia-Wen Ko, PhD, Jiaxi Zhou, MS, Yutao Gong, PhD, Yuan Li Shen, PhD, Rajeshwari Sridhara, PhD, Albert B. Deisseroth, MD PhD, Ann T. Farrell, MD, Richard Pazdur, MD, Gideon Blumenthal, MD

Blood (2018) 132 (Supplement 1): 2670.

https://doi.org/10.1182/blood-2018-99-119678

Published: 2018

Journal Articles

Vector Prime-Protein Boost Vaccine Induces 20 Fold Decrease in the Levels of CD44 + CD24 −/Low Cancer Stem Cells in Epithelial Neoplasms

Yucheng Tang, MD, PhD, Hakan Akbulut, MD, Jonathan Maynard, Pingchaun Li, PhD, Albert B. Deisseroth, MD, PhD

Blood (2008) 112 (11): 2908.

https://doi.org/10.1182/blood.V112.11.2908.2908

Published: 2008

Journal Articles

TAA/ecdCD40L VPP Vaccination Induces Robust Adaptive Immune Response Even in Individuals with Post Transplantation Lymphopenia

Tae Hae Han, MD, PhD, Yucheng Tang, MD, PhD, Yeon Hee Park, MD, Jonathan Maynard, Pingchuan Li, PhD, Hakan Akbulut, MD, Line Petersen, Albert B. Deisseroth, MD, PhD

Blood (2008) 112 (11): 363.

https://doi.org/10.1182/blood.V112.11.363.363

Published: 2008

Journal Articles

Vector Prime-Protein Boost Vaccine Induces Immune Response Against “Self-Antigens” Associated with Epithelial Neoplasms and Tumor Vascular Endothelial Cells.

Yucheng Tang, MD, PhD, Jonathan Maynard, Hakan Akbulut, MD, Phyllis-Jean Linton, PhD, Albert B. Deisseroth, MD, PhD

Blood (2005) 106 (11): 5533.

https://doi.org/10.1182/blood.V106.11.5533.5533

Published: 2005

Journal Articles

Loss of Imprinting in Disease Progression in Chronic Myelogenous Leukemia

Gurvaneet S. Randhawa, Hengmi Cui, Janet A. Barletta, Liora Z. Strichman-Almashanu, Moshe Talpaz, Hagop Kantarjian, Albert B. Deisseroth, Richard C. Champlin, Andrew P. Feinberg

Blood (1998) 91 (9): 3144–3147.

https://doi.org/10.1182/blood.V91.9.3144

Published: 1998

NARROW

Second Cancers in Adults with Acute Promyelocytic Leukemia (APL) Treated with or without Arsenic Trioxide (ATO): A SEER-Medicare Analysis

Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA)

Response Rate, Event-Free Survival (EFS), and Overall Survival (OS) in Newly-Diagnosed Acute Myeloid Leukemia (AML): U.S. Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses

Vector Prime-Protein Boost Vaccine Induces 20 Fold Decrease in the Levels of CD44 + CD24 −/Low Cancer Stem Cells in Epithelial Neoplasms

TAA/ecdCD40L VPP Vaccination Induces Robust Adaptive Immune Response Even in Individuals with Post Transplantation Lymphopenia

Vector Prime-Protein Boost Vaccine Induces Immune Response Against “Self-Antigens” Associated with Epithelial Neoplasms and Tumor Vascular Endothelial Cells.

Loss of Imprinting in Disease Progression in Chronic Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

Second Cancers in Adults with Acute Promyelocytic Leukemia (APL) Treated with or without Arsenic Trioxide (ATO): A SEER-Medicare Analysis

Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA)

Response Rate, Event-Free Survival (EFS), and Overall Survival (OS) in Newly-Diagnosed Acute Myeloid Leukemia (AML): U.S. Food and Drug Administration (FDA) Trial-Level and Patient-Level Analyses

Vector Prime-Protein Boost Vaccine Induces 20 Fold Decrease in the Levels of CD44 + CD24 −/Low Cancer Stem Cells in Epithelial Neoplasms

TAA/ecdCD40L VPP Vaccination Induces Robust Adaptive Immune Response Even in Individuals with Post Transplantation Lymphopenia

Vector Prime-Protein Boost Vaccine Induces Immune Response Against “Self-Antigens” Associated with Epithelial Neoplasms and Tumor Vascular Endothelial Cells.

Loss of Imprinting in Disease Progression in Chronic Myelogenous Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only